Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrđan Verstovšek, Mihaela Lazaroiu, Miklós Egyed et al.|The Lancet|2023Cited by 181
Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World StudyFrancesca Palandri, Massimo Breccia, Elena Maria Elli et al.|Cancer|2024Cited by 10
Ruxolitinib after fedratinib failure in patients with myelofibrosis: A real‐world case seriesFrancesca Palandri, Mario Tiribelli, Filippo Branzanti et al.|British Journal of Haematology|2024Cited by 6
Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinibFrancesca Palandri, Andrew Kuykendall, Filippo Branzanti et al.|Cancer|2025Cited by 5
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter studyFrancesca Palandri, Elisabetta Abruzzese, Massimo Breccia et al.|Leukemia Research|2025Cited by 4